Strand V, et al. - In this randomized controlled trial, researchers analyzed the data to examine the health-related quality of life (HRQOL) in subjects with giant cell arteritis (GCA) treated with tocilizumab (TCZ). They observed improvement in the least squares mean (LSM) changes in Physical Component Summary (PCS) scores with TCZ-QW + Pred-26 but worsened in both PBO + Pred groups at week 52. They noted an improvement in SF-36 and FACIT-Fatigue scores among candidates with GCA receiving TCZ-QW + Pred-26 as compared to those receiving prednisone only. They also noticed recovery of HRQOL to levels at least equivalent to those of A/G-matched normal values at week 52 whereas observed exceeded normal values in 5 of 8 domains due to improvements in the TCZ-QW + Pred-26 group.